+100,756.0%
AMAT vs GSK
+1,721.8%
+99,034.3%
-85.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.2% | -0.2% | +4.4% | +4.3% |
| 7D | -14.7% | +1.7% | -16.4% | -15.3% |
| 30D | -36.1% | +7.0% | -43.1% | -38.1% |
| 3M | -36.9% | -2.7% | -34.2% | -36.9% |
| 6M | -22.2% | +1.4% | -23.6% | -24.2% |
| YTD | +29.9% | +5.3% | +24.6% | +23.9% |
| 1Y | +43.3% | +10.6% | +32.6% | +33.8% |
| 3Y | +142.7% | +62.6% | +80.1% | +87.1% |
| 5Y | +126.2% | +41.7% | +84.5% | +81.0% |
| 10Y | +1,211.7% | +104.7% | +1,107.0% | +799.0% |
| All | +100,756.0% | +1,721.8% | +99,034.3% | +27,314.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling